Taken together, these results suggested that the combined treatment of LTX-315 with PD-1/PD-L1 blockage therapy synergistically inhibited tumor growth and enhanced the infiltration of lymphocytes into the tumor and local immune response. The gene discussed is PDCD1; the disease is neoplasm.